Blog
    Regulatory UpdateFor PhysiciansJuly 22, 2026

    FDA Category 2 Peptides and GLP-1 RA Safety Signals

    Review FDA status for BPC-157, TB-500, and GHK-Cu, alongside emerging safety signals for GLP-1 receptor agonists including NAION and pulmonary aspiration.

    Clinical Question

    What is the current regulatory status of commonly used peptides under FDA 503A and 503B compounding regulations, and what safety signals have been identified through postmarketing surveillance and clinical trials?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and several growth hormone secretagogues are classified as FDA Category 2 bulk substances, rendering them ineligible for routine compounding due to safety or immunogenicity concerns.
    • GLP-1 RA Safety Signals: Strong FAERS signals for gastrointestinal events (nausea, vomiting, delayed gastric emptying) and emerging signals for intestinal obstruction, pulmonary aspiration, and NAION.
    • Clinical Efficacy (Semaglutide/Tirzepatide): Phase III trials demonstrate 14.9% to 22.5% weight loss and significant MACE reduction (20%).
    • Negative Outcomes: Thymosin Alpha-1 failed to show mortality reduction in a Phase III sepsis trial (NCT02867267).

    What the Research Shows

    Evidence from regulatory records as of March 2026 indicates a significant shift in the availability of compounded peptides. The FDA has placed several substances, including BPC-157, TB-500, and GHK-Cu, into Category 2. BPC-157 is cited for having significant safety risks and immunogenicity concerns. Similarly, TB-500 is noted for a lack of human exposure data and immunogenicity risk.

    Regulatory actions have also targeted growth hormone secretagogues. CJC-1295, Ipamorelin, and Selank saw their nominations withdrawn and were removed from eligibility in September 2024. The FDA specifically cited issues such as increased heart rate regarding CJC-1295. While substances like Selank and Semax are approved in Russia, they remain Category 2 substances in the U.S. regulatory framework.

    Regarding approved GLP-1 receptor agonists (RAs), clinical trial data for Semaglutide (STEP 1) and Tirzepatide (SURMOUNT-1) show robust efficacy in weight loss, with Tirzepatide showing superiority in head-to-head trials (SURMOUNT-5). However, postmarketing data (FAERS) highlights significant safety signals. There are 187,757 GLP-1 RA reports through 2023. Beyond expected gastrointestinal symptoms, emerging signals include intestinal obstruction (ileus) and pulmonary aspiration, the latter of which was added to the Ozempic label in 2025 due to risks during general anesthesia. Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is currently an emerging signal with 96 cases through December 2024, prompting an EMA review in January 2025.

    Mechanism

    The provided data does not contain specific molecular mechanism of action records for these peptides beyond clinical outcomes and safety signals.

    Limitations of the Evidence

    The regulatory status of several peptides, such as Thymosin Alpha-1, remains in transition under interim policies, with its status removed pending advisory review as of September 2024. For TB-500, the FDA emphasizes a total lack of human exposure data, limiting the ability to assess clinical safety. Furthermore, while NAION and suicidal ideation are under evaluation for Semaglutide, current data for suicidal ideation do not support a higher risk compared to background rates. The clinical trial for Thymosin Alpha-1 in sepsis (NCT02867267) provided negative results regarding mortality, contradicting earlier expectations for the compound.

    Clinical Takeaway

    Physicians should note that BPC-157, TB-500, and GHK-Cu are currently classified by the FDA as Category 2 substances due to immunogenicity and safety risks, making them ineligible for routine compounding. For approved GLP-1 RAs, while efficacy in obesity and CV outcomes is established, clinicians must monitor for emerging signals of intestinal obstruction and NAION, and manage perioperative risks related to delayed gastric emptying and pulmonary aspiration.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2) - March 2026.
    • FAERS Safety Signals (Semaglutide) - 2024/2025 data.
    • Clinical Trial Records: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT04881706 (Retatrutide), NCT02867267 (Thymosin Alpha-1).

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.